Last week, the Fda announced that it had officially approved Spravato, a brand-name nasal spray containing esketamine, a chemical cousin of ketamine, to treat depression. The drug was hailed by many as a game-changer, as it’s proven to be an effective therapy for people with treatment-resistance depression (Trd), or approximately 30-percent of all people with depression. But how effective is it at actually curing the illness, and approximately when could it become a viable long-term solution for the estimated 16.2 million adults with depression? Here’s what you need to know.
- 3/11/2019
- by EJ Dickson
- Rollingstone.com
Similar News
An Unstable Man Starts To See Monsters All Around Him in This Short Film Corporate Monsters
- 10/5/2019
- by Joey Paur
- GeekTyrant
DEA Didn’t Do Enough to Stop Opioid Epidemic: Report
- 10/1/2019
- by Brenna Ehrlich
- Rollingstone.com
John Oliver Enlists Method Man, Michael Bolton to Highlight Dangers of Compounding Pharmacies
- 9/30/2019
- by Ryan Reed
- Rollingstone.com
Bruce Willis’ Family Shares Dementia Update: It’s ‘Hard to Know’ Whether He’s Aware of His Condition
- 9/25/2023
- by Larisha Paul
- Rollingstone.com
See Al Roker’s Hilarious Reaction When Told How Often People Should Shower
- 7/19/2023
- TV Insider
US scientists decode why our hairs turn grey
- 4/21/2023
- by Agency News Desk
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.